How would you approach adjuvant chemotherapy for high grade pleomorphic/dedifferentiated liposarcoma?

These are not impressive results for a retrospective study where I am sure fitter patients are probably selected for therapy. these are very toxic drugs.

Can you break down the numbers of pleomorphic in this abstract ( unpublished) to see if we can get a better idea

What level of evidence should we be making such toxic treatment recommendations, surely only a peer-reviewed manuscript

therefore 48 patients only were pleomorphic.

in fact, the survivors could easily be the not so bad actors and we may be hurting patients. in their last days of life.

I think we have to learn to say no without data, particularly when for years chemotherapy has been so marginal in soft tissue sarcoma in adults in the stage 4 setting